Valuation : Novacyt

Market Cap 36.4M 42.27M 34.17M 31.2M 58.6M 4.02B 59.02M 405M 158M 2.04B 159M 155M 6.75B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 38.35M 44.54M 36.01M 32.87M 61.75M 4.24B 62.2M 427M 166M 2.15B 167M 164M 7.12B EV / Sales 2026 *
1.26x
EV / Sales 2027 * 1.18x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
Current month+18.85%
1 month+18.85%
3 months+18.85%
6 months+18.85%
Current year+11.84%
1 month 0.57
Extreme 0.5705
0.57
Current year 0.48
Extreme 0.48
0.57
1 year 0.48
Extreme 0.48
0.57
3 years 0.48
Extreme 0.48
1.25
5 years 0.48
Extreme 0.48
5.77
10 years 0
Extreme 0
16
Manager TitleAgeSince
Chief Executive Officer 53 30/04/2024
Director of Finance/CFO 44 31/12/2019
Chief Operating Officer - 31/10/2021
Director TitleAgeSince
Director/Board Member 75 02/07/2006
Director/Board Member 60 26/06/2017
Director/Board Member 44 01/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 42.27M
+0.89%+6.32%-36.86%-38.81% 662M
-3.02%+0.18%+85.84% - 346M
+1.23%-5.99%-33.94%-7.81% 130M
-4.08%-6.00%-27.97%+24.50% 76.43M
Average -1.00%+1.25%-3.23%-7.38% 303.66M
Weighted average by Cap. -0.48%+3.29%-1.01%-28.59%

Financials

2026 *2027 *
Net sales 30.52M 35.45M 28.66M 26.16M 49.15M 3.37B 49.5M 340M 132M 1.71B 133M 130M 5.66B 34.86M 40.49M 32.73M 29.88M 56.13M 3.85B 56.53M 388M 151M 1.95B 152M 149M 6.47B
Net income - -
Net Debt 1.96M 2.27M 1.84M 1.68M 3.15M 216M 3.17M 21.76M 8.47M 110M 8.53M 8.34M 363M 4.84M 5.62M 4.55M 4.15M 7.8M 535M 7.85M 53.87M 20.96M 271M 21.12M 20.66M 898M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216

Annual profits - Rate of surprise